May 2015, Volume 1, Issue 5

May 2015

Volume 1, Issue 5

This issue features a look at new tactics for fighting the cancer drug pricing bloat, a debate on fludarabine in CLL, a report from ASH’s Sickle Cell Disease Summit, and more.

Table of Contents

May 2015

My First Eosinophil

Friday, May 1st, 2015
When a shocking historic event occurs, many can remember exactly where they were and what they were doing when they heard the terrible news....

Work-Life Balance: Something’s Gotta Give

Friday, May 1st, 2015
Today, the term “work-life balance” is ubiquitous in discussions about our working lives, and everyone has an opinion about its validity, how we can...

Managing Penicillin Allergies: The Infectious Disease Specialist’s Perspective

Friday, May 1st, 2015
What advice would you give to hematologists in interpreting a patient’s report of penicillin allergy? Penicillin allergies are very commonly self-reported, by up to 5...

A Collaborative Inpatient Model of Hematology Care

Friday, May 1st, 2015
The integration of advanced practice providers (APPs) – physician assistants (PAs) and nurse practitioners (NPs) – into academic and private hematology and oncology practices...

May 2015

ASH Announces “Bridge Funding” Recipients, CRTI in Latin America Participants

Friday, May 1st, 2015
ASH Announces Recipients of the Fifth Round of Bridge Grants Eleven new blood disease researchers have been selected as the latest recipients of the American...

NCCN Awards Latest Round of Young Investigators, and more

Friday, May 1st, 2015
NCCN Awards Latest Round of Young Investigators With $150,000 Grants The National Comprehensive Cancer Network (NCCN) Foundation has awarded grants to six young investigators from NCCN Member...

May 2015

Efforts to Protest High Cancer Drug Prices Underway

Friday, May 1st, 2015
There is an inconvenient truth when it comes to the cost of new cancer therapies in the United States: The median U.S. household income...

Mind the Gap: The ACA’s Medicaid Expansion Provision Leaves Vulnerable Patients Uncovered

Friday, May 1st, 2015
A key element of the Patient Protection and Affordable Care Act (ACA) was the expansion of the Medicaid program, designed to provide financial assistance...

Demystifying Genomic Panels for Hematologic Malignancies

Friday, May 1st, 2015
It seems as if every medical journal, and even President Obama’s “State of the Union” address earlier this year, mentions “precision” medicine, “targeted” therapies,...

A Voice in the Crowd: Cynthia Dunbar, MD

Friday, May 1st, 2015
Have you always been interested in music and singing? I grew up performing music – playing flute, playing piano, singing – and when I started...

Pulling Back the Curtain: Laurie Sehn, MD

Friday, May 1st, 2015
What was your first job? My first job ever was at the concession stand of a movie theater. I absolutely loved it. It combined two...

Is Fludarabine Dead in CLL?

Friday, May 1st, 2015
A few short years ago, fludarabine was considered the gold standard of front-line treatment for chronic lymphocytic leukemia (CLL), providing better response rates than...

May 2015

Diagnosing the “Problematic Trainee”

Friday, May 1st, 2015
In my early years as program director, my approach to difficult or unprofessional trainees was very black-and-white: There were very clear rules and very...

How Does Cancer Develop?

Friday, May 1st, 2015
Nearly one out of every two Americans will be diagnosed with cancer in his or her lifetime, and worldwide, cancer incidence is predicted to...

What should the duration of anticoagulation be for a patient with idiopathic renal infarct?

Friday, May 1st, 2015
Clinical Dilemma:  David Garcia, MD: This month, David Garcia, MD, advises on the length of anticoagulation in a patient with an idiopathic renal infarct.I have a...

May 2015

WIB_icon

Cord Blood Cell Fucosylation Bolsters Transplant Capabilities

Friday, May 1st, 2015
Although cord blood transplantation (CBT) is a viable alternative for patients lacking an HLA-matched donor, using cord blood as a source of stem cells...
WIB_icon

HCT Remains Best Bet for High-Risk Primary Myelofibrosis

Friday, May 1st, 2015
Physicians treating patients with primary myelofibrosis have one curative treatment option: hematopoietic cell transplantation (HCT). The procedure, can be associated with significant morbidity and...

New Blood or Old: Do Storage Times of Red Blood Cells Impact Patient Outcomes?

Friday, May 1st, 2015
Red blood cells (RBCs) undergo numerous changes as they are stored – some of which may impair their ability to increase oxygen delivery, which...

NOAC Reversal Agent Granted Priority Review, New Drug for Rare Type of Leukemia, and...

Friday, May 1st, 2015
Dabigatran Reversal Agent Idarucizumab Granted Priority Review by the FDA The U.S. Food and Drug Administration has granted priority review to the biologics license application...
WIB_icon

Similar Outcomes with Different Daunorubicin Doses in AML

Friday, May 1st, 2015
The combination of cytosine arabinoside (Ara-C) and an anthracycline has held its ground as the standard induction therapy for acute myeloid leukemia (AML) for more...

MRD Levels Mid-Remission: The Key to Better Prognosis for ALL Patients?

Friday, May 1st, 2015
(MRD) that persists following remission induction chemotherapy afor acute lymphocytic leukemia (ALL) is a powerful prognostic factor, new research shows that determining MRD levels...
WIB_icon

Gene Therapy Proves Promising for Children with “Bubble Boy” Disease

Friday, May 1st, 2015
Treatment of X-linked severe combined immunodeficiency (SCID-X1), a rare immune disorder also known as “bubble boy disease,” often involves stem cell transplantation from a...

Congress Repeals SGR Bill. What Now?

Friday, May 1st, 2015
In April 14, 2015, the U.S. Senate passed the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) by an overwhelming bipartisan majority –...

Oral ABL001 in CML, poloxamer 188 in vaso-occlusive crisis of SCD, and more

Friday, May 1st, 2015
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute...

A New Era for Waldenström’s Macroglobulinemia Treatment

Friday, May 1st, 2015
In the more than 70 years since Jan G. Waldenström discovered Waldenström's macroglobulinemia, there have been few answers about what causes the malignant B-cell...
WIB_icon

Childhood ALL Survivors Struggle with Obesity and Long-Term Fitness Deficits

Friday, May 1st, 2015
In the past few decades, treatment of childhood acute lymphoblastic leukemia (ALL) has been recognized as one of the true success stories in hematologic...

High-Cost Surveillance Imaging Falls Short on Survival Benefit in DLBCL

Friday, May 1st, 2015
Surveillance imaging to monitor patients with diffuse large B-cell lymphoma (DLBCL) in first remission may be common practice, but a new cost-effectiveness analysis has...

May 2015

Single-Agent Ibrutinib Leads to Durable Responses in CLL

Friday, May 1st, 2015
In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), single-agent ibrutinib led to durable responses, according to...

Pediatric Leukemia Patients May Benefit from CAR Therapy

Friday, May 1st, 2015
Genetically reprogrammed T cells, which have been making waves in adult acute lymphocytic leukemia (ALL), have also shown promise in pediatric ALL patients, according...

Updates on Novel Treatments for Leukemia

Friday, May 1st, 2015
Three sessions at the American Association for Cancer Research Annual Meeting focused on promising, novel treatment options for patients with various forms of leukemia. In...

Study Evaluates Safety of Cytotoxic T Lymphocytes for Rituximab-Refractory Epstein-Barr Virus

Friday, May 1st, 2015
For patients who have undergone stem cell or organ transplantation, the drugs administered to prevent organ rejection can weaken the immune system, which can...

ASH Sickle Cell Disease Summit: A Call to Action

Friday, May 1st, 2015
In mid-April, more than 60 experts in sickle cell disease (SCD), including clinicians and researchers, federal agency partners, representatives from industry, and other members...

SHARE